Strand Fredrik
Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
Medical Diagnostics Karolinska, Karolinska University Hospital, Solna, Sweden.
Jpn J Radiol. 2025 Jun;43(6):927-933. doi: 10.1007/s11604-025-01734-4. Epub 2025 Jan 11.
Artificial intelligence (AI) has emerged as a transformative tool in breast cancer screening, with two distinct applications: computer-aided cancer detection (CAD) and risk prediction. While AI CAD systems are slowly finding its way into clinical practice to assist radiologists or make independent reads, this review focuses on AI risk models, which aim to predict a patient's likelihood of being diagnosed with breast cancer within a few years after negative screening. Unlike AI CAD systems, AI risk models are mainly explored in research settings without widespread clinical adoption. This review synthesizes advances in AI-driven risk prediction models, from traditional imaging biomarkers to cutting-edge deep learning methodologies and multimodal approaches. Contributions by leading researchers are explored with critical appraisal of their methods and findings. Ethical, practical, and clinical challenges in implementing AI models are also discussed, with an emphasis on real-world applications. This review concludes by proposing future directions to optimize the adoption of AI tools in breast cancer screening and improve equity and outcomes for diverse populations.
人工智能(AI)已成为乳腺癌筛查中的一种变革性工具,有两种不同的应用:计算机辅助癌症检测(CAD)和风险预测。虽然人工智能CAD系统正逐渐进入临床实践以协助放射科医生或进行独立解读,但本综述重点关注人工智能风险模型,其旨在预测患者在筛查结果为阴性后的几年内被诊断为乳腺癌的可能性。与人工智能CAD系统不同,人工智能风险模型主要在研究环境中进行探索,尚未广泛应用于临床。本综述综合了人工智能驱动的风险预测模型的进展,从传统的影像生物标志物到前沿的深度学习方法和多模态方法。探讨了 leading researchers 的贡献,并对他们的方法和发现进行了批判性评估。还讨论了实施人工智能模型时的伦理、实际和临床挑战,重点是实际应用。本综述最后提出了未来的方向,以优化人工智能工具在乳腺癌筛查中的应用,并改善不同人群的公平性和筛查结果。